Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Moderate to Severe Plaque Psoriasis With Scalp Involvement
Phase 4
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: EtanerceptBiological: Placebo
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 124
- Registration Number
- NCT00791765
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Phase 1
Completed
- Conditions
- Low Grade LymphomaHodgkin's LymphomaLymphomaMantle Cell LymphomaNon-Hodgkin's LymphomaDiffuse Large Cell Lymphoma
- Interventions
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 33
- Registration Number
- NCT00791011
A Study of AMG 557 in Adults With Systemic Lupus Erythematosus
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 58
- Registration Number
- NCT00774943
- Locations
- 🇨🇦
Research Site, Newmarket, Ontario, Canada
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
Phase 2
Completed
- Conditions
- PsoriasisPlaque-type Psoriasis
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 352
- Registration Number
- NCT00773734
- Locations
- 🇺🇸
Stanford University School of Medicine, Redwood City, California, United States
🇺🇸NorthShore University HealthSystem, Skokie, Illinois, United States
🇺🇸Dermatology Associates, Los Angeles, California, United States
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- CancerCastrate-Resistant Prostate CancerMestastatic Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 162
- Registration Number
- NCT00770848
Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: BrodalumabOther: Placebo
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 40
- Registration Number
- NCT00771030
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Phase 1
Completed
- Conditions
- CancerFallopian Tube CancerOncologyOvarian CancerSolid TumorsCarcinomaTumorsGynecological MalignanciesMetastases
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2015-09-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 103
- Registration Number
- NCT00770536
- Locations
- 🇧🇪
Research Site, Wilrijk, Belgium
Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis
Phase 1
Completed
- Conditions
- Atopic DermatitisHealthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 78
- Registration Number
- NCT00757042
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase 2
Completed
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 67
- Registration Number
- NCT00756444
A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: MP-376 (Levofloxacin solution for Inhalation)Drug: Placebo
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT00752414
© Copyright 2025. All Rights Reserved by MedPath